Clinical trials: Cytomegalovirus
CMV Viremia
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation and commonly presents as an…
- Trial name
- CYPHER-TXPilot (NCT05432778)
- Testing
- Letermovir Pill
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- University Medical Centre Ljubljana
Cytomegalovirus Infections
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
The goal of STAGE I of the CMV TransmIT Study is to determine the prevalence of CMV shedding in children up to and including 36 months of age in large group childcare centers and in staff who regularly work at the center.
- Trial name
- NCT06522880
- Testing
- CMV PCR on saliva
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Cytomegalovirus Retinitis, HIV Infections
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002169
- Testing
- Nelfinavir mesylate
- Where
- 8 sites in United States
- Sponsor
- Agouron Pharmaceuticals
CMV
Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
Cytomegalovirus (CMV) is the most common member of the herpes viruses to infect humans. Its double-stranded linear DNA duplex contains 165 genes that encode viral proteins that mimic and interact with human cellular proteins and…
- Trial name
- CMV-ICU (NCT04280380)
- Testing
- Real time PCR
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fundación de investigación HM
Double-stranded DNA Virus
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es).
- Trial name
- NCT01143181
- Testing
- Brincidofovir
- Where
- 37 sites in United States
- Volunteers
- 210 people
- Sponsor
- Jazz Pharmaceuticals
Patients Who Have Received Allo-HSCT
Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
This study aim at examining whether blocking platelet-derived growth factor receptor-α by imatinib lowers the risk of post-allogeneic hematopoietic stem cell transplantation CMV infection.
- Trial name
- NCT03343600
- Testing
- Imatinib
- Where
- 5 sites in Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Congenital Cytomegalovirus Infection, Cytomegalovirus Infection Reactivation
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China
The purpose of this study is to assess the risk of congenital cytomegalovirus (cCMV) infection in newborns born to seropositive women.
- Trial name
- NCT02645396
- Where
- 2 sites in China
- Volunteers
- 8,855 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Cytomegalovirus Viraemia
Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients
The study will prospectively determine the clinical utility of CMV cell-mediated immunity using the Quantiferon test. The investigators will use the assay results to tailor the duration of CMV prophylaxis in solid organ…
- Trial name
- QFT-CMV (NCT02784756)
- Testing
- Quantiferon-CMV assay
- Where
- 6 sites in Canada, Spain
- Volunteers
- 134 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
Objectives of this trial are to: Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne challenge (3000 pfu) in healthy CMV-seronegative volunteers who receive VCL CT02 administered (1 mg weekly x 3) 3…
- Trial name
- NCT00373412
- Testing
- VCL CT02 pDNA vaccine, Towne CMV vaccine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Cytomegalovirus Infections, Solid Organ Transplant
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
- Trial name
- NCT03950414
- Testing
- CMV specific T-cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison
CMV, Congenital Cmv
Cytomegalovirus Shedding Characteristics in Pregnant Women
The cCHIPS study is a feasibility study for larger scale multi-centre studies and is designed as a single-centre observational cohort, longitudinal, natural history study.
- Conditions
- CMV, Congenital Cmv, Maternal Infections Affecting Fetus or Newborn, Shedding Virus
- Trial name
- cCHIPS (NCT04021628)
- Testing
- No intervention- not applicable
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- St George's, University of London
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
Cytomegalovirus Infections
CMV Glycoprotein B Vaccine in Allograft Recipients
Patients who receive transplants are at increased risk of developing serious cytomegalovirus (CMV) infections because they have a decreased immune system.
- Trial name
- NCT00299260
- Testing
- CMV gB vaccine
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University College, London
Allograft
Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen
Traditionally known for their role in haemostasis, platelets have also an immune role. Platelets play a key role in immune mediator secretion, and interact with innate and adaptive immune cells, contributing to the fight against…
- Trial name
- FIPALLOC (NCT03009708)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Institut de Cancérologie de la Loire
Cytomegalovirus Retinitis, HIV Infections
The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS
AMENDED: To evaluate the effect of sargramostim ( GM-CSF ) on modulating the granulocytopenia associated with concomitant DHPG and AZT therapy ( Phase B ), in terms of time to development of granulocytopenia as defined by an…
- Trial name
- NCT00000989
- Testing
- Zidovudine, Sargramostim, Ganciclovir
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Infections, Cytomegalovirus, Cytomegalovirus Infections
Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus
This study is designed to evaluate maternal virological and immunological parameters to determine their ability to predict congenital cytomegalovirus (CMV) infection.
- Trial name
- NCT01251744
- Testing
- Blood sample, Cord blood sample, Saliva swab
- Where
- 9 sites in Belgium
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
Cytomegalovirus (CMV) Infection, Kidney Transplant Recipient
Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in…
- Trial name
- RESPECT-CMV (NCT07488481)
- Testing
- SYN002
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infections
Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell Transplants
The purpose of this study is to test the safety of a transfusion of specialized white cells from your transplant donor's blood, called T-cells, that have been grown and immunized against the CMV virus in the test tube.
- Trial name
- NCT00674648
- Testing
- CMV-Peptide-Specific T cells
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center